Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com

by · The Cerbat Gem

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Read Our Latest Stock Analysis on ORMP

Oramed Pharmaceuticals Trading Up 2.1 %

Oramed Pharmaceuticals stock opened at $2.47 on Wednesday. The company has a market capitalization of $100.35 million, a PE ratio of 9.50 and a beta of 1.77. The stock has a 50-day moving average price of $2.43 and a two-hundred day moving average price of $2.48. Oramed Pharmaceuticals has a 12 month low of $1.67 and a 12 month high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.21. As a group, analysts predict that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of large investors have recently bought and sold shares of ORMP. XTX Topco Ltd bought a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Assenagon Asset Management S.A. bought a new position in Oramed Pharmaceuticals in the 1st quarter valued at about $54,000. Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals during the 1st quarter worth approximately $68,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

(Get Free Report)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

Featured Stories